trending Market Intelligence /marketintelligence/en/news-insights/trending/X5GQu1xa06ZabJg4bBV71g2 content esgSubNav
In This List

SK Capital acquires Perrigo's active pharmaceutical ingredients business

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


SK Capital acquires Perrigo's active pharmaceutical ingredients business

Perrigo Co. plc's active pharmaceutical ingredients business was renamed to Wavelength Pharmaceuticals after U.S. private investment firm SK Capital completed the acquisition.

Wavelength produces generic active pharmaceutical ingredients, with primary operations in Israel and supporting functions in the U.S. and India.

Apollo Global Management and its affiliates along with MidCap Financial provided debt financing for the transaction. RBC Capital Markets LLC and Rothschild acted as SK Capital's joint advisers.